FY2026 Earnings Forecast for TLX Issued By William Blair

Key Points

• William Blair has reduced its FY2026 earnings per share (EPS) estimate for Telix Pharmaceuticals from $0.28 to $0.15, while maintaining an "Outperform" rating on the stock.
• The consensus estimate for Telix's full-year earnings currently stands at $0.24 per share, reflecting a significant downgrade from earlier estimates.
• Telix Pharmaceuticals has received a mix of ratings from analysts, with four Buy ratings and one Hold rating, resulting in a consensus rating of "Moderate Buy" with a price target of $22.33.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Equities researchers at William Blair reduced their FY2026 earnings per share (EPS) estimates for Telix Pharmaceuticals in a note issued to investors on Thursday, August 28th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of $0.15 per share for the year, down from their previous estimate of $0.28. William Blair has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share.

A number of other research analysts have also recently commented on the company. HC Wainwright began coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price target on the stock. Wedbush reissued an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $22.33.

Telix Pharmaceuticals Price Performance

NASDAQ TLX opened at $9.55 on Monday. The stock's 50 day moving average is $13.92 and its 200 day moving average is $16.03. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66. Telix Pharmaceuticals has a 12 month low of $9.48 and a 12 month high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals during the 1st quarter worth about $170,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $213,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $297,000. Finally, ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals during the 1st quarter worth about $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.